Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 310

Results For "IP"

10384 News Found

Biogen to invest $2 billion to expand manufacturing capability in North Carolina
News | July 21, 2025

Biogen to invest $2 billion to expand manufacturing capability in North Carolina

Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date


Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl
Clinical Trials | July 19, 2025

Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl

Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use


Vimta Labs Q1 FY26 PAT climbs to Rs. 18.89 Cr
News | July 18, 2025

Vimta Labs Q1 FY26 PAT climbs to Rs. 18.89 Cr

Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025


Zigly launches its first pet hospital in Mumbai
News | July 18, 2025

Zigly launches its first pet hospital in Mumbai

The new Zigly center features and offers comprehensive veterinary services


Kenvue collaborates with API to launch India’s first cough clinics
Healthcare | July 18, 2025

Kenvue collaborates with API to launch India’s first cough clinics

Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough


Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2
Drug Approval | July 18, 2025

Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2

The company is addressing these observations comprehensively


Concord Biotech announces successful completion EU GMP inspection at its API facility
News | July 18, 2025

Concord Biotech announces successful completion EU GMP inspection at its API facility

This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance


Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru
Drug Approval | July 17, 2025

Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru

This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms